Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer
Open Access
- 17 March 2015
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 22 (6) , 590-595
Abstract
Objectives: To examine the effects of combined treatment with sulfoquinovosylacylpropanediol and X‐ray irradiation on the remodeling of the prostate cancer microenvironment, including angiogenic and hypoxic characteristics.Methods: Human prostate cancer cells (DU145 and PC3) were implanted subcutaneously into the right hind legs of athymic nude mice. After the tumor volume reached 100–300mm3, 2mg/kg/day sulfoquinovosylacylpropanediol was given intravenously from day0 to day4, and cells were exposed to 4Gy X‐ray irradiation on days0 and 3 (for a total of 8Gy). Tumors were fixed and stained for pathological analyses and immunohistochemical evaluations. To analyze vascular normalization, 60mg/kg pimonidazole dissolved in saline was injected intraperitoneally.Results: Combined treatment with sulfoquinovosylacylpropanediol plus X‐ray irradiation enhanced growth inhibition in DU145 xenografts. The tumor vessel density in DU145 cells significantly decreased after the combined treatment. Staining for αsmooth muscle actin in vessels was significantly increased. Pimonidazole staining, showing hypoxic lesions, was negative from 72h, but positive at 6 and 24h after the first combined treatment. In contrast, no enhancement of the microenvironment in PC3 xenografts was observed with sulfoquinovosylacylpropanediol plus X‐ray irradiation.Conclusion: Sulfoquinovosylacylpropanediol could be a novel potent radiosensitizing agent targeting angiogenesis in prostate cancer.Keywords
This publication has 27 references indexed in Scilit:
- Epidemiology of prostate cancer in the Asia-Pacific regionProstate International, 2013
- Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiformeRadiation Oncology, 2013
- Factors Implicated in Radiation Therapy Failure and Radiosensitization of Prostate CancerProstate Cancer, 2011
- Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenograftsJournal of Clinical Investigation, 2011
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Clinical Oncology, 2010
- Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinomaBritish Journal of Cancer, 2010
- The Akt/mTOR Pathway Assures the Synthesis of HIF-1α Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated TumorsJournal of Biological Chemistry, 2009
- α-Sulfoquinovosylmonoacylglycerol Is a Novel Potent Radiosensitizer Targeting Tumor AngiogenesisCancer Research, 2006
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Sulfoquinovosyldiacylglycerol, KM043, a New Potent Inhibitor of Eukaryotic DNA Polymerases and HIV-Reverse Transcriptase Type 1 from a Marine Red Alga, Gigartina tenella.Chemical and Pharmaceutical Bulletin, 1998